IP Library › Granted Patent US 11,338,042
Granted Patent B2
US 11,338,042 · App. 16/701,184 · Granted May 24, 2022

Immunoparticles and methods of generating and using same

Inventors: Ranit Kedmi (Tel-Aviv, IL); Dan Peer (Kiryat-Ono, IL)
Assignee: Ramot at Tel-Aviv University Ltd.
A61K47/6809A61K47/6849A61K47/6851A61K47/6897A61K47/6909A61K47/6921B82Y5/00C07K16/2809C07K16/2812C07K16/2839C07K16/2896C07K16/30C07K16/4283A61K2039/505C07K2317/622C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,338,042
App. No.
16/701,184
Granted
May 24, 2022
Kind
B2
Abstract

A pharmaceutical composition comprising an immunoparticle is provided. The pharmaceutical composition comprising a monoclonal secondary antibody immunocomplexed with a primary antibody, wherein said monoclonal secondary antibody is coupled on an outer surface of a particle and wherein said particle is loaded with a pharmaceutical agent.

Claims (11)

1. A method of delivering a pharmaceutical agent to a subject in need thereof, the method comprising administering to the subject an immunoparticle comprising a humanized secondary antibody coupled on an outer surface of a particle, wherein said secondary antibody is bound specifically to an Fc region of an isolated humanized or human primary antibody and wherein said immunoparticle is loaded with the pharmaceutical agent, thereby delivering the pharmaceutical agent to the subject.

2. The method of claim 1 , wherein said administering is systemically administering.

3. The method of claim 1 , wherein said isolated humanized secondary antibody is an IgG.

4. The method of claim 1 , wherein said humanized or human primary antibody is IgG1.

5. The method of claim 1 , wherein said primary antibody comprises an antigen recognition region which binds a tissue specific antigen.

6. The method of claim 1 , wherein said primary antibody comprises an antigen recognition region which binds a cancer specific antigen.

7. The method of claim 1 , wherein said particle is selected from the group consisting of a polymeric particle, a microcapsule, a liposome, a microsphere, a microemulsion, a nanoparticle, a nanocapsule, a nanosphere and a nanocage.

8. The method of claim 1 , wherein said particle comprises a charged external surface.

9. The method of claim 1 , wherein said particle comprises a neutral external surface.

10. The method of claim 1 , wherein said particle is lipid-based particle.

11. The method of claim 1 , wherein said subject is a human subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2019
From: KEDMI, RANIT; PEER, DAN
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 051255/0658 →
Priority Claims (1)
IL 221909 · Sep 12, 2012 · national
Continuity (2)
Division 14427711
Related Publication 20200101170A1 · Apr 2, 2020
Cited By (1)
US 12,668,643